Editorial
1061 Standardisation in clinical laboratory medicine: an ethical reflection
X Bossuyt, C Louche, A Wiik

Hypothesis
1064 A biography of the chondrocyte
P A Sinkin

Extended reports
1069 Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus
M Nikpour, A A Dempsey, M B Urowitz, D D Gladman, D A Barnes

1076 CCL3/LT gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythematosus
M Mantami, B Revin, R Brey, J F Camargo, H Kulkarni, M Herrera, P Correa, S Holliday, J-M Anayt, S K Ahuja

1084 Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
H K Genant, C G Peterfy, R Westhoven, J-C Becker, R Aranda, G Vratisanos, J Teng, J M Kremer

1090 Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
G A W Bruyn, G Tate, F Cattani, J Mallonado-Cocco, B Westhoven, H Tannebaum, M Bell, O Forre, O Bjornbom, P P Tah, R H Abeywickrama, P Berhardt, P L C van Riel, for the RADD study group

1096 Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
M Schiff, M Keiserman, C Coding, S Sengchonhara, A Berman, S Navijager, C Saldate, T Li, R Aranda, J-C Becker, C Lin, P L N Cernet, M Dougados

1104 Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial
P L C M van Riel, B Freundlich, D MacPeek, R Pedersen, J R Feoh, A Singh, on behalf of ADORE study investigators

1111 Genetic variations in the serotonin 5-HT2a receptor gene (HTR2A) are associated with rheumatoid arthritis
A Kling, M Saddighchedah, I Arlestig, L Alfredsson, S Rentapää-Dahlqvist, L Padyukov

1116 Can ultrasonography improve on radiographic assessment in osteoarthrosis of the hands? A comparison between radiographic and ultrasonographic detected pathology
H I Keen, R J Wakefield, A J Grainger, E M A Hensor, P Emery, P G Conaghan

1121 Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension
F Ianone, M T Riccardi, S Gaiducci, R Bizzocca, M Cinelli, M M Patriuzzi-Cerino, G Lapadula

1127 Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis
B J J Radavits, J Fransen, P L C M van Riel, R F J M Laan

1132 B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor α antagonists: differential effects between good and poor clinical responders
D T La, C E Collins, H-T Yang, T-S Migeon, W Stohl

1139 The clinical response to infliximab in rheumatoid arthritis is part dependent on pretreatment tumour necrosis factor α expression in the synovium

1145 Focus on adverse events of tumour necrosis factor α blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients
V Gerloni, I Pontikaki, M Gattinara, F Fantini

1153 Efficient management of rheumatoid arthritis significantly reduces long-term functional disability
E Tanaka, A Manmatiithara, E Inoue, M Hara, T Tomatsu, N Kamatai, G Singh, H Yamana

1159 A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis

1165 Inmate production of tumour necrosis factor α and interleukin 10 is associated with radiological progression of knee osteoarthritis

Cover image: Genant-modified Sharp scoring system. Coloured areas indicate sites used to evaluate erosion and joint space narrowing scores (p1084).

Editor
Tore K Kvien

Associate Editors
Francis Berenbaum
Hans Bjørsmo
Dimitrios Boumpas
Gerd Burmester
Mary Crow

Editorial office
Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 6.411

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics. ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors’ institutions, the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2008 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd, typeset by The Charlesworth Group and printed in the UK on acid-free paper from sustainable forests by Cambrian Printers Limited, Aberystwyth, UK.

Annals of the Rheumatic Diseases (ISSN Nos: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by SPP, 75 Aberdeen Road, Emigsville, PA 17318, USA. Periodicals postage paid at Emigsville, PA, USA. POSTMASTER: send address changes to Annals of the Rheumatic Diseases, PO Box 437, Emigsville, PA 17318-0437, USA.

THE EULAR JOURNAL

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics
www.publicationethics.org.uk

More Contents ➤